|
NEWS
----- Press Release -----
Upperton
Acquires New Research Facilities
Upperton Limited has acquired access to
research and development facilities, based at the University
of Nottingham, UK
14th FEBRUARY 2000
Nottingham, UK -- Upperton,
a newly-created research and development company specialising
in the development of contrast agents for in vivo diagnostic
imaging, has reached agreement with academics at the
University of Nottingham to access research facilities.
This
development is a major step forward for the emerging
company and provides Upperton with all the facilities
needed to develop products from concept through to early-stage
clinical testing.
Founder
and chief executive, Dr Richard Johnson, was particularly
delighted in this new development. Formerly a founding
Director of Andaris Limited, Dr Johnson sees the emerging
Upperton as an ideal vehicle from which to exploit a
number of novel, exciting product opportunities.
Upperton
is exploiting its proprietary microsphere and nanosphere
technology to create a new generation of novel contrast
agents for the diagnosis of disease in humans. These
contrast agents will enable existing imaging modalities
to detect and diagnose disease at a much earlier stage
than can be achieved by imaging machines alone.
To
best exploit its technology, Upperton is seeking to
collaborate with a select number of established diagnostic
imaging companies.
-----
End -----
|
